The role of small firms in US biotechnology clusters

被引:89
作者
Audretsch, DB [1 ]
机构
[1] Indiana Univ, Inst Dev Strategies, Bloomington, IN 47405 USA
基金
美国国家卫生研究院;
关键词
Medical Research; Growth Process; Commercialize Product; Small Firm; Venture Capital;
D O I
10.1023/A:1011140014334
中图分类号
F [经济];
学科分类号
02 ;
摘要
The biotechnology industry poses a particular challenge to analysis because its origins were poorly understood or even noticed at the time. The purpose of this paper is to examine and make sense of recent developments in the U.S. biotechnology industry. The pioneers and subsequent followers in biotechnology came from other fields. They altered their career trajectories in sciences like genetics and medical research to enter an unknown and undefined field, which only subsequently became labeled as biotechnology. Those regions exhibiting the greatest success in developing biotechnology clusters also possessed the greatest ability to unleash the potential commercialization latent in those scientists. To generate a successful regional cluster, the existence of world class scientific talent is a necessary condition. However, it is not a sufficient condition. The ancillary or complementary factors must also be available to translate this knowledge into a commercialized product. The complementary factors include the presence of venture capital and other forms of finance, the existence of an entrepreneurial culture, and transparent and minimal regulations fostering the start-up and growth processes.
引用
收藏
页码:3 / 15
页数:13
相关论文
共 18 条
[1]  
[Anonymous], 1993, BIOTECHNOLOGY REV
[2]  
Audretsch D., 1999, INNOVATION IND EVOLU, P216
[3]  
Audretsch DB, 1996, AM ECON REV, V86, P630
[4]  
Audretsch DB, 1996, AM ECON REV, V86, P641
[5]  
Audretsch DB., 1995, INNOVATION IND EVOLU
[6]  
AUDRETSCH DB, 2000, EVALUATING IMPACT US
[7]  
BLAKELY EJ, 1993, BIOTECHNOLOGY REV, V1, P11
[8]  
*BOARD SCI TECHN E, 1999, UNPUB GOV IND PARTN
[9]  
BURRILL GS, 1987, BIOTECH 88 MARKETPLA
[10]  
BURRILL GS, 1992, BIOTECH 93 ACCELERAT